Ensuring Timely Access to Generics Act of 2019
This bill requires the Food and Drug Administration (FDA) to consider certain factors in determining whether a petition is submitted for the primary purpose of delaying the approval of a drug application.
The FDA must (1) publish a list of petitions that were submitted with an intent to delay, and (2) establish procedures to refer such petitions to the Federal Trade Commission.
The FDA may establish a timeline for submitting petitions.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2019-05-02 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2019-05-01 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2019-05-01 | IntroReferral | Introduced in House | Library of Congress |